

M.H

14

PATENT COOPERATION TREATY

PCT

REC'D 18 FEB 2000
WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/KR 98/00259	International filing date (day/month/year) 25 August 1998 (25.08.98)	Priority Date (day/month/year) 28 August 1997 (28.08.97)
International Patent Classification (IPC) or national classification and IPC IPC⁶: C 12 N 7/00; C 12 N 7/08; A 61 K 39/12		
Applicant CHEIL JEDANG CORPORATION et al.		

<p>1. This international preliminary examination report has been prepared by this International Preliminary Examination Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>4</u> sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of _____ sheets.</p> <p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input checked="" type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application

Date of submission of the demand 25 March 1999 (25.03.99)	Date of completion of this report 01 December 1999 (01.12.99)
Name and mailing address of the IPEA/AT Austrian Patent Office Kohlmarkt 8-10 A-1014 Vienna Facsimile No. 1/53424/200	Authorized officer Wolf Telephone No. 1/53424/436

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/KR 98/00259

I. Basis of the report

1. With regard to the elements of the international application:*

the international application as originally filed

the description:

pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

the claims:

pages _____, as originally filed
 pages _____, as amended (together with any statement) under Article 19
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

the drawings:

pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

the sequence listing part of the description:

pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

the language of publication of the international application (under Rule 48.3(b)).

the language of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

the description, pages _____.

the claims, Nos. _____.

the drawings, sheets/fig _____.

5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as „originally filed“ and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORTInternational application No.
PCT/KR 98/00259**IV. Lack of unity of invention**

1. In response to the invitation to restrict or pay additional fees the applicant has:

- restricted the claims.
- paid additional fees.
- paid additional fees under protest.
- neither restricted nor paid additional fees.

2. This Authority found that the requirements of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirements of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

- complied with.
- not complied with for the following reasons:

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- all parts.
- the parts relating to claims Nos.

INTERNATIONAL PRELIMINARY EXAMINATION REPORTInternational application No.
PCT/KR 98/00259**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. Statement**

Novelty (N)	Claims	<u>1-7</u>	YES
	Claims	_____	NO
Inventive step (IS)	Claims	<u>1-7</u>	YES
	Claims	_____	NO
Industrial applicability (IA)	Claims	<u>1-7</u>	YES
	Claims	_____	NO

2. Citations and explanations (Rule 70.7)

The following documents are cited in the international search report:

D1 JP 2-223 531 A
D2 EP 0 562 136 A1
D3 JP 1-117 780 A

D1 and D2 relate to Japanese encephalitis virus and to vaccines to said virus. In D3 a recombinant vaccina virus giving a Japanese encephalitis vaccine is described.

In none of these documents an attenuated Japanese encephalitis virus adapted to Vero cell (claim 1 of the present application) or a vaccine comprising such attenuated virus (claim 4) is described or suggested. Therefore, the documents cited above merely represent the general state of the art with regard to claims 1 and 4 of the application. Furthermore, said document do not reveal or suggest the subject-matters of claims 2, 3 and 5-7.

Thus, the subject-matters of claims 1-7 of the present international application comply with the requirements of novelty and inventive step. The industrial applicability of said subject-matters is self-evident.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 98/00259

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: C 12 N 7/00,7/08; A 61 K 39/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: C 12 N 7/00,7/08; A 61 K 39/12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPODOC, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Patent Abstracts of Japan, Vol.14, No.535, 1990, JP 2-223531 A (TEKADA CHEM. IND., LTD.) 26 November 1990 (26.11.90), abstract.	1,4
A	EP 0 562 136 A1 (DIVISION OF MICROBIOLOGY, KYOTO BIKEN LABORATORIES, INC.) 29 September 1993 (29.09.93), abstract.	1,4
A	Patent Abstracts of Japan, Vol.13, No.339, 1989, JP 1-117780 A (NIPPON ZOKI PHARMACEUT CO., LTD.) 31 July 1989 (31.07.89), abstract.	1,4

Further documents are listed in the continuation of Box C.

See patent family annex.

Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
15 December 1998 (15.12.98)

Date of mailing of the international search report
13 January 1999 (13.01.99)

Name and mailing address of the ISA/
Austrian Patent Office
Kohlmarkt 8-10; A-1014 Vienna
Facsimile No. 1/53424/535

Authorized officer
Wolf
Telephone No. 1/53424/436

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. application No.

PCT/KR 98/00259

Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A1 562136	29-09-93	keine - none - rien	

INTERNATIONAL SEARCH REPORT

Int'l application No.

PCT/KR 98/00259

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: C 12 N 7/00,7/08; A 61 K 39/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: C 12 N 7/00,7/08; A 61 K 39/12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPDOC, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Patent Abstracts of Japan, Vol.14, No.535, 1990, JP 2-223531 A (TEKADA CHEM. IND., LTD.) 26 November 1990 (26.11.90), abstract.	1,4
A	EP 0 562 136 A1 (DIVISION OF MICROBIOLOGY, KYOTO BIKEN LABORATORIES, INC.) 29 September 1993 (29.09.93), abstract.	1,4
A	Patent Abstracts of Japan, Vol.13, No.339, 1989, JP 1-117780 A (NIPPON ZOKI PHARMACEUT CO., LTD.) 31 July 1989 (31.07.89), abstract. -----	1,4

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input checked="" type="checkbox"/> See patent family annex.
* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
15 December 1998 (15.12.98)	13 January 1999 (13.01.99)
Name and mailing address of the ISA/ Austrian Patent Office Kohlmarkt 8-10; A-1014 Vienna Facsimile No. 1/53424/535	Authorized officer Wolf Telephone No. 1/53424/436

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inventor's name / application No.

PCT/KR 98/00259

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A1 562136	29-09-93	keine - none - rien	

PATENT COOPERATION TREATY

**From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY**

To:

CHOI, Hak Hyun and
HWANG, Ju Myung
6th Floor, Peeres Building,
222, 3-ka, Chungjung-ro,
Seodaemun-ku
Seoul 120-013
Republic of Korea

PCT

**NOTIFICATION CONCERNING PAYMENT OF
THE PRELIMINARY EXAMINATION
AND HANDLING FEES**

(PCT Rules 57 and 58 and
Administrative Instructions, Section 615)

	Date of mailing (day/month/year) 18 August 1999 (18.08.99)
Applicant's or agent's file reference	PAYMENT DUE see item 3 for time limit
International application No. PCT/KR 98/00259	International filing date (day/month/year) 25 August 1998 (25.08.98)
Applicant Cheil Jedang Corporation et al.	

1. The applicant is hereby notified that this International Preliminary Examining Authority has received:

the payment of all the prescribed fees, and an overpayment, which will be refunded in due course.

no or insufficient payment of the prescribed fees and the applicant is hereby **invited to pay the balance due**, as summarized under item 2, within the time limit indicated under item 3.

ATTENTION: Applicant must pay bank fees.

2. Fees and payment calculation:

Preliminary

examination fee ATS 2.200,- P

Handling fee* + ATS 2.020,-- H

* Applicants from certain States are entitled to a reduction of 75% of the handling fee. Where the applicant is (or all applicants are) so entitled, the amount to be entered at H is 25% of the handling fee. See Notes to the Fee Calculation Sheet annexed to the Demand Form, PCT/IPEA/401, for details.

3. Time limit for payment and amount payable (Rules 57.3 and 58.1(b)):

within ONE MONTH from the date on which the demand was submitted (see below), in which case the amount payable is the amount applicable on that date of submittal:

within ONE MONTH from the date of receipt (see below) of the demand by this Authority (where the demand was transmitted to this Authority under Rule 59.3), in which case the amount payable is the amount applicable on that date of receipt:

Name and mailing address of the IPEA/AT Austrian Patent Office Kohlmarkt 8-10; A-1014 Vienna	Authorized officer Hofbauer
Facsimile No. 1/53424/200	Telephone No. 1/53424/225

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION
(PCT Rule 61.2)

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year)
22 April 1999 (22.04.99)

International application No.
PCT/KR98/00259

International filing date (day/month/year)
25 August 1998 (25.08.98)

Applicant's or agent's file reference

Priority date (day/month/year)
28 August 1997 (28.08.97)

Applicant

KIM, Hyun, Su et al

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

25 March 1999 (25.03.99)

in a notice effecting later election filed with the International Bureau on:

2. The election was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Lazar Joseph Panakal
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 7/00, 7/08, A61K 39/12		A1	(11) International Publication Number: WO 99/11762 (43) International Publication Date: 11 March 1999 (11.03.99)
<p>(21) International Application Number: PCT/KR98/00259</p> <p>(22) International Filing Date: 25 August 1998 (25.08.98)</p> <p>(30) Priority Data: 1997/42001 28 August 1997 (28.08.97) KR 1997/42002 28 August 1997 (28.08.97) KR </p> <p>(71) Applicants (<i>for all designated States except US</i>): CHEIL JEDANG CORPORATION [KR/KR]; 500, 5-ga, Namdaemun-ro, Chung-ku, Seoul 100-095 (KR). WALTER REED ARMY INSTITUTE OF RESEARCH [US/US]; 14th and Dahlia Streets, N.W., Washington, DC 20307-5100 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): KIM, Hyun, Su [KR/KR]; Shindong-A Apt. 32-707, Gil 2-dong Kangdong-ku, Seoul 134-766 (KR). YOO, Wang, Don [KR/KR]; Daerim Apt. 108-1001, Daebang-dong, Dongjak-ku, Seoul 156-020 (KR). KIM, Soo; Ok [KR/KR]; Plaza Apt. 10-601, Garak-dong, Songpa-ku, Seoul 138-160 (KR). LEE, Sung, Hee [KR/KR]; Hankuk Apt. 102-808, Maitan 2-dong, Paldal-ku, Suwon, Kyungkido 442-372 (KR). MOON, Sang, Bum [KR/KR]; San 522-1, Dukpyungri, Majangmyun, Yicheon, Kyungkido 467-810 (KR). HONG, Sun, Pyo [KR/KR]; Daejin Apt. 106-502, 339,</p>		<p>Jukjunri, Suji-up, Yongin, Kyungkido 449-840 (KR). SHIN, Yong, Cheol [KR/KR]; Samhogarden Apt. 2-809, Banpo 1-dong, Seocho-ku, Seoul 137-761 (KR). CHUNG, Yong, Ju [KR/KR]; Hyundae Apt. 104-1504, Shindaebang 1-dong, Dongjak-ku, Seoul 156-011 (KR). ECKELS, Kenneth, H. [US/US]; Walter Reed Army Institute of Research, Washington, DC 20307-5100 (US). INNIS, Bruce [US/US]; Walter Reed Army Institute of Research, Washington, DC 20307-5100 (US). PUTNAK, Joseph, R. [US/US]; Walter Reed Army Institute of Research, Washington, DC 20307-5100 (US). BINN, Leonard, N. [US/US]; Walter Reed Army Institute of Research, Washington, DC 20307-5100 (US). SRIVASTAVA, Ashok, K. [US/US]; Walter Reed Army Institute of Research, Washington, DC 20307-5100 (US). DUBOIS, Doria, R. [US/US]; Walter Reed Army Institute of Research, Washington, DC 20307-5100 (US).</p> <p>(74) Agents: CHOI, Hak, Hyun et al.; Peeres Building, 6th floor, 222, 3-ka, Chungjung-ro, Seodaemun-ku, Seoul 120-013 (KR).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: AN ATTENUATED JAPANESE ENCEPHALITIS VIRUS ADAPTED TO VERO CELL AND A JAPANESE ENCEPHALITIS VACCINE</p> <p>(57) Abstract</p> <p>The present invention relates to an attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell and a Japanese encephalitis vaccine comprising said attenuated virus.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**AN ATTENUATED JAPANESE ENCEPHALITIS VIRUS
ADAPTED TO VERO CELL AND
A JAPANESE ENCEPHALITIS VACCINE**

5

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

10 The present invention relates to an attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell and a Japanese encephalitis vaccine comprising said attenuated virus.

DESCRIPTION OF THE PRIOR ART

15 Japanese encephalitis (JE) is a mosquito-borne arboviral disease of major public health importance in Asia. More than 35,000 cases and 10,000 deaths are reported annually from that continent, but official reports undoubtedly underestimate the true number of cases (Okuno, T. *World Health Stat Q.* 3: 120-31, 1978; Umenei, T. *et al. Bull World Health Org.* 63: 625-31, 1985). The illness may be manifested by a febrile headache syndrome, aseptic meningitis, or encephalitis and about half of the survivors tend to have permanent neurologic and psychiatric sequelae (Burke, D.S. *et al. The Arbovirus: Epidemiology and Ecology* 3:63-92, 1988; Monath, T.P. *Virology* 763-814, 20

1990).

25 JE virus is one of 66 Flaviviridae, enveloped, positive-sense, single stranded RNA viruses that largely are vector-borne (Chambers, T. J. *et al. Ann. Rev. Microbiol.* 44:649-88, 1990). Morphologically, flaviviruses are spherical, approximately 40 nm in diameter, are composed of a lipid bilayer surrounding a nucleocapsid containing 11-kb genome complexed with a capsid (C) protein (Rice, C. M. *et al. Science* 229:726-33, 30 1985). Surface projections on the membrane are composed of glycosylated envelope (E)

5

and membrane (M) proteins. A pre-M glycoprotein, present in intracellular nascent virions, is cleaved to the M protein, found in mature extracellular virions. Important physiological activities are associated with the 53-kd E protein, including hemagglutination, viral neutralization, virion assembly, membrane fusion, and viral binding to cellular receptors (Koshini, E. *et al. Virol.* 188:714-20, 1992).

10

There are three JE vaccines for humans (Tsai, T. *et al. Vaccines* 671-713, 1993). Of the three, only inactivated JE vaccine produced in mouse brain is available internationally. One manufacturer, the Research Foundation for Microbial Diseases of Osaka University (Biken) produces most of the inactivated JE vaccine distributed internationally; that vaccine was licensed in 1992 in the USA where it is distributed by Connaught Laboratories, Inc., as JE-VAXTM. Inactivated and live attenuated JE vaccine prepared in primary hamster kidney (PHK) cells are distributed solely in China.

15

Inactivated JE vaccine produced in mouse brains was licensed in Japan in 1954. Because it is produced by cerebral injection of infant mice, it is laborious to manufacture and concerns about the possibility of vaccine-related neurological side effect were raised. Though successive refinements in the manufacturing process have increased its purity and potency (Oya, A. *Vaccination Theory and Practice* 69-82, 1975; Oya, A. *Acta Pediatr Jpn.* 30:175-84, 1988; Takaku, K. *Biken J.* 11:25-39, 1968), a moderate frequency of local and mild systemic reactions have been reported until recently (Hoke, C.H. *et al. New Engl J Med.* 319:608-14, 1988; Poland, J.D. *et al. J Infect Dis.* 161:878-82, 1990; Sanchez, J.L. *et al. Lancet* 335:972-73, 1990). Local tenderness, redness, and/or swelling at the injection site occur in 20 % of vaccines. Mild systemic symptoms, chiefly headache, low-grade fever, myalgias, malaise, and gastrointestinal symptoms, are reported by 10 to 30 % of vaccines. An apparently new pattern of adverse reactions including urticaria, angioedema, respiratory distress, erythema multiforme, erythema nosodum and severe neurological disorders have been reported since 1989, principally among travellers vaccinated in Australia, Europe, and North America (Anderson, M.M. *et al. Lancet.* 337:1044, 1991; Ruff, T.A. *et al. Lancet* 228:881-2, 1991). In addition, in 1992 and 1995 Ohtaki reported seven children with

acute disseminated encephalomyelitis (ADEM) with changes on magnetic resonance images (MRI) after JE vaccination (Ohtaki, E. *et al.* *Pediatr Neurol.* 8:137-9, 1992; Ohtaki, E. *et al.* *J Neurol Neurosurg Psychiatry* 59:316-7, 1995). Also of note is that vaccination with rabies vaccine containing animal brain tissue has caused severe
5 neurological complications (Plotkin, S.A. *et al.* *Vaccines* 661-2, 1994). For these reasons, the WHO has designated JE vaccine development as a high priority.

More recently, inactivated and live attenuated JE vaccine of China have proven to be effective, eliciting high titers of virus-neutralizing antibody and conferring solid
10 protection (Tsai, T. *et al.* *Vaccines* 671-713, 1993). However, PHK cells in which Chinese vaccine were prepared are not approved by the World Health Organization (WHO) for viral vaccine production or licensed for human use by the developed countries. The principal disadvantage in using primary hamster cells for the production of vaccines is the uncertainty with regard to the quality of vaccine. Even if specific
15 pathogen free hamsters are used, animals can unexpectedly become infected, being problematic for vaccine production. Occasionally an infection of this type could be undetected for a long time. With these criticisms, further controlled studies of the safety of the vaccine are required to allow confidence regarding its widespread use. Another disadvantage of the vaccine production from primary cells is the low rate of harvest of
20 the virus and high cost without allowing mass production.

In view of the above, there is a need for new JE vaccine which is produced in standard cell lines such as Vero or human diploid cells that have been accepted as human vaccine substrates, with good cost effectiveness. Vero cells are transformed but
25 non-tumorigenic cells derived from monkey kidney. The Vero cell line is more advantageous than any other standard cell line in that Vero cells are more readily adaptable to large scale cell culture and as a transformed cell has an infinite life time.

It has now been found that JE virus can be grown in Vero cell culture.
30 Considerable efforts had been made in the field of JE vaccine to produce vaccine in standard cells which permit effecting cell cultures at a large volume. Nevertheless, virus

5

characterization including genetic stability, yield and process necessary for vaccine commercialization through cultivation with Vero cells had never met the requirements of human vaccine. Owing to these facts and to the difficulties of transposing a knowledge acquired in other virus cultures to JE virus, the prior art had not achieved success in the development of JE virus vaccine which is genetically stable and has a high immunogenic character from continuous cell lines. Among all these researches, none had resulted up to the present time in a new vaccine production which satisfies the criteria mentioned in this background.

10

The present invention suggests a development and a propagation of JE virus in continuous cell line, Vero cells for vaccine production which overcome previous problems in JE virus produced in mouse brain or primary cell lines. The present invention also identifies methodology developed to cultivate the JE virus and a downstream process for vaccine production with cost-effectiveness.

15

In addition, the present invention identifies methodology improved upon the previously commercialized JE vaccines in the following ways.

20

1. Safety: The invented virus did not acquire the virulence through the Vero cell cultivation, reducing the hazards of production and affording an additional level of safety to recipients beyond that furnished by stringent control over the virus-inactivation process. This advantage has never been provided by the previously commercialized JE vaccines.

25

2. Increased supply in safer production substrate: The JE vaccine of the present invention is produced in the absence of bovine serum, making high yields and inexpensive and scalable production which are not achieved in the the previously commercialized JE vaccines.

30

3. Less reactogenicity: No gelatin stabilizer is incorporated into the JE vaccine of the present invention, reducing the risk of vaccine reactions like those seen

with the existing vaccine (Saskaguchi M. et al. *Vaccines* 68-69, 1998). In addition, undesirable bovine-derived components, incorporated in the existing JE vaccines are effectively eliminated. Conclusively, this safety point of the present invention has never been provided by the previous JE vaccine.

5

4. Increased potency: The success of scalable production with Vero cells and the absence of supplements for production, as well as the effective purification, permits the first use of potent adjuvants in formulating the JE vaccine. Although the use of the adjuvants in the vaccine formulation has been applied in other vaccine, transposing this knowledge to the JE vaccine has been in difficulty since none of the existing JE vaccines assure it's safe production.

10

In conclusion, none had resulted up to the present time in a new vaccine which satisfies the aforementioned advantages in the commercialization of JE vaccine.

15

Therefore, an object of the present invention is to provide a safe and effective JE vaccine produced in standard cell substrate to increase its acceptability in many countries. A further object of the invention is to provide an effective process for producing a highly purified stable vaccine and formulating a vaccine which has a high immunogenic character with a small antigen amount.

20

SUMMARY OF THE INVENTION

25

In one aspect, the present invention provides an attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell. The attenuated Japanese encephalitis virus of the present invention, which is referred to as CJ50003 herein, was deposited at the permanent collection of the Korean Culture Center of Microorganisms, Seoul, Korea, on April 20, 1998 under the Budapest Treaty of the international recognition of the deposit of microorganisms for the purpose of patent procedure, and a subculture thereof can be obtained from the repository under the accession number KCCM-10125.

30

In another aspect, the present invention provides a Japanese encephalitis vaccine comprising an attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell.

5 **BRIEF DESCRIPTION OF THE DRAWINGS**

These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description, appended claims, and accompanying drawings as follows:

10

Figure 1 shows passages and adaptation of JE virus SA14-14-2(PDK) in Vero cells. Virus passage 1 was harvested at 5 days after inoculation of Vero cell monolayer with 0.1 moi of SA14-14-2(PDK) strain. The JE virus titer was measured by plaque assay performed on Vero cell monolayers. Subsequent serial passages were conducted to 30 passages with virus passage 1 virus as starting material by successive virus infection and titration as described in Example 1.

15

Figure 2 shows multiple time harvest of JE virus CJ50003 in a roller bottle every other day from 3 to 17 days post infection. Vero cell monolayer were infected at a moi of 0.01 plaque forming unit (pfu) per cell. Virus was allowed to adsorb for 2 hrs at 35°C, then cells were washed with PBS three times, fed with 100 ml of serum-free EMEM and incubated at 35°C. Every 48 hrs from 3 days to 17 days post inoculation, culture supernatants were replaced with fresh serum-free EMEM. Virus infectivity titrations of the harvests were performed by plaquing on Vero-cell monolayers.

20

Figure 3 shows an analysis of JE virus CJ50003 purified by sucrose gradient ultracentrifugation by SDS-PAGE and Western blotting. Sixty ml of concentrated culture supernatant was applied to a forty ml of 15-60% sucrose gradient and centrifuged in a 45 Ti rotor at 22,000 rpm, 18 hrs., 12°C. Two ml samples were collected from the bottom of the tube and subjected to 4-20 % gradient SDS-PAGE and the resolved proteins were transferred to Nitrocellulose membranes. Proteins were

25

visualized by staining with Coomassie brilliant blue (Panel A) or silver nitrate (Panel B), and antigens were visualized by reaction with monoclonal antibody reactive against JE viral E protein (Panel C). Lane 1, pre-stained protein standards (Novex SeeblueTM) representing molecular weights of 250, 98, 64, 50, 36, 30, 16, and 6 kDa from the top; 5 Lane 2-10, fraction No. 3-11 from the bottom after ultracentrifugation; E, envelope protein; C, capsid protein; M, membrane protein.

Figure 4 shows formaldehyde inactivation kinetics of purified JE virus CJ50003. Purified JE virus preparations were inactivated with 0.018 % formaldehyde at 4°C or 10 22°C. Samples taken at the indicated times were titrated for their residual infectious virus by direct plaquing on Vero cell monolayers. Additionally, amplification assay was done to detect low levels of virus as follows. Duplicate flasks containing Vero cell monolayers were inoculated with samples from virus-inactivation time points. After a 2 hr adsorption period at 35°C, cells were refed and incubated at 35°C. Cells were refed 15 at 7 days and at 14 days post-infection. The culture media were harvested and plaqued to detect infectious virus. Inactivation time points from two separate experiments are shown: 4°C (filled rectangle), 22°C (filled circle). Thermal inactivation (no formaldehyde) controls (open rectangle for 4°C and open circle for 22°C) were done in parallel.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a JE virus strain which has desirable properties for the preparation of the JE vaccine. Said virus is an attenuated virus and can propagate in the continuous cell line, Vero which is admitted by WHO as cell substrate for human 25 vaccine production. Thus it is expected that said virus can be used for the preparation of more safe inactivated and live JE vaccines than current vaccines.

The present invention provides a vaccine that satisfies the present need. A JE 30 virus has been adapted to Vero cell by serial passages at no higher than 35°C. Continued passages in Vero cell resulted in increase in virus titer, over 10⁷ pfu per ml of culture

supernatant and reduced culture time to show peak virus titer. The invention concerns the development of a multiple time harvesting process with no serum requirement as supplement resulted in high yield of virus productivity, which is commercially feasible properties for the large-scale production of said vaccine with cost-effectiveness.

5 According to the invention, the multiple harvesting process in virus cultivation is responsible for the reduced degree of cytopathic effect (CPE) of infected cells. The JE vaccine of the present invention contains an extremely small quantity of residual cell derived components owing to the reduced level of CPE. In addition, JE vaccine of the present invention is expected to afford enhanced immunogenicity and greater protection
10 against disease than current JE vaccines. The purified JE vaccine of the present invention has a major advantage over current vaccines in that the purified viruses from the cultured Vero cells meet the development requirements for human vaccine.

The present invention also relates to the methods for the preparation of said
15 vaccine. The methods can provide high productivity, purity and potency of said vaccine. The JE virus CJ50003 is obtained by subjecting JE virus SA14-14-2(PDK) to 4 passages or more of adapting in the Vero tissue culture cells at temperatures no higher than 35°C and selecting the cultured virus while monitoring the virus propagation based on the number of foci which were formed in Vero and/or LLC-MK2 cells. The virus
20 obtained from that adaptation has a peak titer of at least 1×10^7 pfu/ml of culture supernatant in Vero cell culture and reduced incubation period for harvest. The JE virus SA14-14-2 is an attenuated strain which is obtained by adapting a wild type JE virus SA14 from mosquito in the Primary Hamster Kidney (PHK) tissue culture cell and the Primary Dog Kidney (PDK) tissue culture cell (Kenneth H. Eckels, et al. *Vaccine* 6 513-518, 1988). But the PHK and PDK cells are not admitted by WHO, so they are not suitable for preparation of vaccines applicable to humans. The Vero cell is admitted by WHO for human use, so the Vero adapted JE virus strain, CJ50003, is a good basis for production of vaccine for humans.

30 It is known that SA14-14-2(PDK) virus belongs to flaviviridae and has the following physicochemical properties: single-stranded, positive-sense RNA genome

with 5' methylated end and 3' end with no poly A structure. The size of RNA genome is approximately 11 kb and the genome is in a combined state with nucleocapsid (C) protein of 13,500 Da. The virus is additionally comprised of membrane (M) protein of 8,700 Da, envelope (E) protein of 53,000 Da and non-structural proteins NS1, 2a, 2b, 5 3, 4a, 5 and the like.

The Vero adapted JE virus strain, CJ50003 was passed in Vero cell over 30 passages. The virus titer and the morphology of plaque were not varied through passaging, suggesting that the virus has stable phenotypic character.

10

To get an insight into the molecular basis for the biological characteristics of JE virus CJ50003, the physicochemical properties of the virus were analyzed. The sequence of the bases of the viral genome was determined by cDNA cloning and sequencing. As a result, it was discovered that three adenine bases of the 1032, 1506, 15 and 1704 positions, and a guanine base of the 1769 position of E protein gene of JE SA14-14-2(PDK) virus were replaced by three guanines and a thymine in JE CJ50003 virus, respectively. Accordingly, the amino acid sequence of E protein was changed from threonine of the 19 position, threonine of the 177 position, lysine of the 243 position and glutamine of the 264 position to alanine, alanine, glutamate and histidine, 20 respectively. The amino acid changes on the E protein were maintained through passaging the virus in Vero cell as long as our investigation lasted.

The JE virus CJ50003 did not kill mice when the viruses which have different number of passages in Vero cells, were injected to young mice intracerebrally. 25 Accordingly, it can be said that the Vero adapted JE virus CJ50003 is an attenuated and stable virus strain which has no or little neurovirulence. It is one of the critical points to use said virus for the live JE virus vaccine and/or inactivated vaccine.

The present invention also provides a method for purifying virus from cell culture without freezing the crude or interim purity materials. Said method comprises the steps of removing cell debris, concentrating the virus, purifying the virus by 30

precipitation of the materials of cell origin and sucrose gradient ultracentrifugation, fractionating the gradients and assaying the fractions for virus. More specifically, the present invention provides a method for the production of purified JE virus, by propagating virus to high titer in continuous cell lines, in the presence or absence of serum protein supplements, purifying the virus by ultracentrifugation, and pooling the virus-positive fractions.

The said virus is propagated in Vero tissue culture cells. The confluently grown Vero cells in roller bottles are infected and incubated with the CJ50003 virus. Harvesting the virus can be done by the multiple harvesting method. The harvest of culture supernatant was started at the point of 2 or 3 days post infection according to moi of infection, and the fresh medium was refed to the culture. After 2 day incubation of the refed culture, the culture supernatant was harvested again. Harvesting can be repeated up to 4 times by 8 or 9 days post infection with the virus titer maintained over 10^7 pfu/ml of culture supernatant. The multiple harvesting method gave a high yield of virus per unit roller bottle, so it makes this invention more compatible with the laws of market. Furthermore, the process is responsible for the reduced degree of CPE of infected cells. The reduced level of CPE contributes to extremely low level of residual cell derived components in JE vaccine of the present invention. The harvested culture supernatants can be stored at 4°C until the purification started. The clarification of the harvested culture supernatants can be accomplished by common methods known in the art including low-speed centrifugation, for example, at 1500 g for 10 min, and/or by filtration through a filter of pore size of 0.45. The harvested culture fluid is stored at 4°C until concentration. For the concentration of the virus, the culture fluid is ultrafiltrated and the retentate is collected. In another method for concentration, the polyethylene glycol (PEG) 8000 is dissolved in the culture fluid up to 10% and the precipitate is dissolved in a proper buffer, for example phosphate-buffered saline (PBS, pH 7.0). The protamine sulfate precipitation is performed for removing DNA or other materials which originated from the cell, which can be accomplished by addition of protamine sulfate to concentrated virus solution and high speed centrifugation, for example, at 12,000 g, for 5 min. For further purification of the virus, density gradient

ultracentrifugation is performed on 15-60% continuous or multi-step sucrose gradients. The sucrose gradient is fractionated and the fractions are assayed for the virus. Methods for assaying for virus positive fractions include plaque assay, hemagglutination assay, polyacrylamide gel electrophoresis, and antigen assays such as immunoassays. The 5 fractions for further processing are pooled on the basis of high virus titer and low level of other impurities. The purity of the pooled purified virus was estimated by testing for Vero cell originated chromosomal DNA and protein. The results showed that contents of host cellular DNA and protein are as low as 2.5 pg and 2 ng per 5 µg of purified JE virus, respectively, which demonstrated the purification methods described above 10 effectively removed other impurities from viral antigen. JE virus yield from 1 L of infected culture fluid is estimated to be about 2.3 milligrams.

The present invention also provides a method of inactivating JE virus to destroy its infectivity while preserving its antigenicity. Said method comprises adding an 15 effective quantity of formaldehyde and incubating said virus with said agent in certain conditions such that said virus is inactivated. Specifically, the fraction pool was diluted to appropriate protein concentration with a proper buffer such as PBS and the formaldehyde was added to the diluted fraction pool. The incubation with formaldehyde was performed at 22°C or 4°C. At least 4 or 46 days were required to fully destroy viral 20 infectivity without loss of viral antigenicity at 22°C or 4°C, respectively. The inactivation process of JE virus at 22°C was preferably chosen for simplicity in large scale culture and incubation time was extended to 7 days for a safety margin. However, examples of inactivating agents which were effective include but are not limited to formaldehyde. In general, this can be achieved by chemical or physical means. 25 Chemical inactivation can be effected by treating the viruses, for example, with enzymes, β-propionlactone, ethylene-imine or a derivative thereof, and an organic solvent such as Tween, Triton, sodium deoxycholate, and sulphohetain. If necessary, the inactivating substance is neutralized afterwards; material inactivated with formaldehyde can, for example, be neutralized with thiosulphate. Physical inactivation can preferably 30 be carried out by subjecting the viruses to energy-rich radiation, such as UV light, X-radiation or gamma-radiation.

The JE vaccines are prepared as injectables, either as liquid solution or suspension. It is possible to add a stabilizing agent such as carbohydrates (sorbitol, mannitol, starch, sucrose, dextran, glucose, etc), proteins (albumins, casein, etc), an agent containing proteins (bovine serum, skim milk, etc) and buffers (such as alkali metal phosphate). The preparation can be lyophilized after adding a stabilizer and it can be vacuum or nitrogen stored. If desired, one or more compounds with an adjuvant action can be added. Suitable compounds for this purpose are, for example, aluminum hydroxide, phosphate or oxide, mineral oil (such as Bayol, Marcol 52) and saponins. In addition, if desired, one or more emulsifiers, such as Tween and span, is also added to the virus materials.

The effectiveness of an adjuvant was determined by measuring the amount of neutralizing antibodies directed against the virus resulting from administration of the inactive virus in vaccines which are also absorbed to an adjuvant. Examples of adjuvant which was effective include but is not limited to alum hydroxide. The obtained vaccine was investigated for efficacy by the plaque reduction neutralization test (PRNT) with the sera of said vaccine immunized mice and direct challenge of immunized mice with a neurovirulent virus. As a result, it was shown that the said vaccine had the same as or better efficacy of eliciting neutralizing antibody than comparable vaccines.

To investigate possible changes in immunogenicity of Vero adapted viruses with different passage numbers, the vaccines were prepared in different passage numbers and the efficacy of each vaccine was compared. There was no remarkable difference in efficacy among the vaccines prepared from viruses with different passage numbers in spite of successive passing in Vero cell. Thus it can be said that the Vero adapted JE virus strain, CJ50003, has stable immunogenicity.

The following examples illustrate the attenuated JE virus adapted to Vero cell according to the present invention and the JE vaccine comprising said attenuated virus according to the present invention. From the foregoing description and the following examples, it is believed that those skilled in the art would be able to carry out the

invention to the fullest extent.

EXAMPLE 1

Adaptation of SA14-14-2(PDK) virus in Vero cell

5

JE SA14-14-2 (PDK), SA14-14-2 virus in dog kidney cell culture passage 8 was used to initiate serial passages in Vero cell culture. The Vero cell monolayers were inoculated with JE SA14-14-2 (PDK) at an moi of 0.1 pfu per cell. The infected cell cultures were grown in 25 cm² culture flasks containing 5 ml of nutrient media consisting of Eagle's minimal essential media supplemented with 10 % fetal bovine serum in an atmosphere of about 5 % CO₂ in air and at a temperature no higher than about 35°C, typically at from about 32°C to about 35°C, with about 35°C being preferred. Viral growth was monitored by microscopic observation of cytopathic effect (CPE) and various assay for the presence of viral antigen including hemadsorption assay (HA), plaque assay, and enzyme linked immunoadsorbant assay (ELISA). JE virus was harvested at day 5 post infection when the culture showed peak of virus titer, clarified by centrifugation. The single plaque was purified from the clarified supernatant and amplified in Vero cells. The amplified virus was re-infected to Vero cell for further passages. Subsequent serial passages were conducted up to 30 passages by successive virus infection, titration, and plaque-purification as described above. As shown in Figure 1, the virus titers reached about 4X10⁷ pfu per ml of culture supernatant with 4 passages in Vero cells and maintained close to this level in further passages. Besides, the optimal period for viral harvest was reduced from 5 days at passage 1 to 2 - 3 days at passage 4. A significant increase in virus yield, about 10⁵ pfu/ml to over 10⁷ pfu/ml and a decrease in incubation time resulted in the selection of the JE passage 4 in Vero cells as starting material of choice for the preparation of a candidate JE vaccine. The JE passage 4 in Vero cells was labelled as CJ50003 (Vero, PS4). Abbreviation PS means virus passage number in designated cell.

20

25

30

EXAMPLE 2

Characterization of CJ50003 virus; Sequencing of the envelope gene and

neurovirulence study

As an effort to give an insight into the molecular basis for the biological characteristic of CJ50003 strain, the 1500 nucleotide sequence encoding the envelope(E) gene which possesses major neutralizing epitopes were determined and compared with those of the parent vaccine strains, SA14-14-2(PDK), SA14-14-2(PHK) and an wild type SA14 virus (Aihira, S. et al. *Virus Genes*, 5:95-109, 1991; Ni, H. et al . *J Gen Virol.* 76:401-407, 1995; Ni, H. et al. *J Gen Virol.* 76:409-413, 1995; Nitayaphan, S. et al. *Virology* 177:541-542, 1990). CJ50003 virus (Vero, PS4) was used for sequence analysis. This revealed that the C-terminal region (amino acid 280-500) shows complete conservation, while the N-terminal region (amino acid 1-279) shows sequence variation among the virus strains. Mutations in the N-terminal region are almost evenly distributed. Nucleotide sequence of the E protein gene of CJ50003 differed from SA14/CDC by 8 nucleotides and 7 amino acids whereas SA14-14-2(PDK) differed from SA14/CDC by 7 nucleotides and 5 amino acids. The results were summarized in Table 1.

The sequence of CJ50003 virus differed from the published sequence of SA14-14-2(PDK) virus at 5 positions: nucleotide changes at positions 1032, 1506, 1704 and 1769 resulted in 4 amino acid differences between SA14-14-2(PDK) and CJ50003 viruses: nucleotide changes at position 989 did not result in amino acid substitution. Higher passages of CJ50003 virus, i.e. passage 15 and 30 revealed no additional nucleotide changes. There were, therefore 5 distinct nucleotide and 4 amino acid changes between CJ50003 and parent virus, SA14-14-2(PDK) and these changes were stable on passage of this virus in cell culture. The Lys residue at 243 in the SA14-14-2(PDK), which is uniquely different compared with other attenuated JE viruses were substituted with Glu residue in CJ50003.

CJ50003 sequence also differed from the published sequence of SA14-14-2(PHK) virus (Aihira, S. et al. *Virus Genes*, 5:95-109, 1991). The nucleotide difference at 1032 caused amino acid difference at position E19 but the change at

nucleotide position 989 did not result in amino acid substitution. Nucleotides at 1506 and 1704 in CJ50003 virus were the same as those present in the SA14-14-2(PHK) at these positions while different from the SA14-14-2(PDK) at those positions. The pattern of substitutions through the N-terminal region of the CJ50003 and
5 SA14-14-2(PHK) E gene is almost same except for amino acid substitution at E19.

SA14-14-2(PHK), SA14-14-2(PDK) and CJ50003 viruses have 4 identical amino acid substitutions compared with the sequence of the parent SA14 virus at position E107, E138, E176 and E279. Of those the amino acids at position E138 and
10 E176 (Ni, H. et al. *J Gen Virol.* 76:409-413, 1995), which were known to contribute to attenuation were still conserved after Vero adaptation, suggesting that CJ50003 did not lose it's attenuated character.

15

20

25

30

Table 1. Comparison of nucleotide and amino acid sequences among JE virus strains, SA14, SA14-14-2(PHK), SA14-14-2(PDK), and CJ50003.

Position	Nucleotide										Amino Acid			
	SA14/ NT	AA	USA	CDC	AP	SA14/J 2/PHK	14- 2/PDK	SA14- CJ50003	USA	CDC	AP	SA14/J 2/PHK	14- 2/PDK	SA14- CJ50003
989	E4	G	G	G	G	U	U	G	Leu	Leu	Leu	Leu	Leu	Leu
1032	E19	A	A	A	A	A	A	G	Thr	Thr	Thr	Thr	Thr	Ala
1052	E25	G	A	A	A	A	A	A	Leu	Leu	Leu	Leu	Leu	Leu
1061	E28	U	U	U	C	C	C	C	Asp	Asp	Asp	Asp	Asp	Asp
1217	E80	C	C	U	U	C	C	C	Ala	Ala	Ala	Ala	Ala	Ala
1296	E107	C	C	C	U	U	U	U	Leu	Leu	Leu	Phe	Phe	Phe
1389	E138	G	G	G	A	A	A	A	Glu	Glu	Glu	Lys	Lys	Lys
1503	E176	A	A	A	G	G	G	G	Ile	Ile	Ile	Val	Val	Val
1506	E177	A	A	A	G	A	G	G	Thr	Thr	Thr	Ala	Thr	Ala
1704	E243	G	G	G	G	G	A	G	Glu	Glu	Glu	Glu	Glu	Glu
1708	E244	G	A	A	A	A	A	A	Glu	Gly	Gly	Gly	Gly	Gly
1769	E264	G	G	G	G	A	G	U	Gln	Gln	Gln	His	Gln	His
1813	E279	A	A	A	U	U	U	U	Lys	Lys	Lys	Met	Met	Met
1921	E315	C	U	C	U	U	U	U	Ala	Val	Ala	Val	Val	Val
1977	E334	C	C	U	C	U	C	C	Pro	Pro	Ser	Pro	Pro	Pro
2293	E439	A	G	A	G	G	G	G	Lys	Arg	Arg	Arg	Arg	Arg
2441	E488	G	A	G	A	A	A	A	Gly	Gly	Gly	Gly	Gly	Gly

AA: amino acid; NT: nucleotide position strains.

5

CJ50003 and the parent SA14-14-2(PDK) were tested for their mice neurovirulence by intracerebral (i.c.) injection into the 4-week-old BALB/c mice. The results are shown in Table 2. The lethality for young adult mice is not significantly different between SA14-14-2(PDK) and CJ50003 viruses which is very low compared to that of wild type SA14 virus. Thus it seems to be that the introduction to the Vero cell substrate did not provide a neurovirulent phenotype to the SA14-14-2(PDK) and CJ50003 virus still has attenuated character.

10

Table 2. Intracerebral virulence of 4-week-old mice inoculated with Vero-passaged CJ50003 viruses. PS represents passage in PDK or Vero cell.

Virus	PFU Inoculum	log LD ₅₀ ml ⁻¹	LD ₅₀ /PFU ratio
SA14(PDK, PS3)	2 x 10(7)	6.5	0.17 ^a
SA14-14-2(PDK,PS8)	1.3 x 10(6)	<1.5 ^b	<0.00002 ^a
CJ50003(Vero, PS6)	3.4 x 10(7)	<1.5 ^b	<0.000001
15 CJ50003(Vero, PS15)	3.2 x 10(7)	<1.5 ^b	<0.000001
CJ50003(Vero, PS30)	3.6 x 10(7)	<1.5 ^b	<0.000001

a: Kenneth H. Eckels *et al* (*Vaccine* 6:513-518, 1988).

b: 0/10 mice died after inoculation with undiluted virus.

The volume of inoculum for i.c. injection is 0.03 ml per mouse.

20

EXAMPLE 3

Virus growth and purification

25

The production seed was prepared in virus passage 5 in Vero cell [CJ50003 (Vero, PS5)]and stored in deep-freezer. Vero cells were grown in Eagle's minimal essential medium (EMEM, Gibco) containing 10% fetal bovine serum (FBS, Gibco). Roller bottle cultures of Vero cell monolayers were infected with production seed virus at an moi of 0.01 to 0.1 pfu per cell. After 2 hours of virus adsorption, the cultures were washed 3 times with PBS and fed with EMEM not containing serum and incubated at 35°C. In infected Vero cell cultures, virus reached titers of around 10⁷ to 10⁸ pfu/ml at 30 2 or 3 days post infection. While virus harvests were taken 4 times at 2 day intervals

until 8 or 9 days post infection starting from 2 or 3 days post infection, virus titers were still maintained over 10^7 pfu/ml with very weak CPE. But after 9 days post infection, the titers were under 10^7 pfu/ml (Figure 2). The pooled harvests were centrifuged at 8,000 rpm for 15 minutes and supernatants were filtered through a $0.45\text{ }\mu\text{m}$ filter. Virus culture supernatants were concentrated by ultrafiltration (Ultrasette, Filtron, 100k) or precipitation with PEG. The virus precipitated by PEG was collected by centrifugation and suspended in PBS or STE (10 mM Tris pH 7.2, 1 mM EDTA, 150 mM NaCl) buffer. Retentate after ultrafiltration was concentrated to 250 ml and the cassette was washed with 100 ml of PBS. Virus concentrates were chilled in the ice for 2 hours after adding 0.5 - 2 mg/ml of protamine sulfate and the supernatants obtained by centrifuging at 10,000 rpm for 5 minutes. The concentrated viruses were purified by ultracentrifugation on sucrose gradients. The ultracentrifugation was carried out at 38,000 g for 18 hours. Fractions were subjected to electrophoresis on polyacrylamide gels containing the detergent sodium dodecyl sulfate (SDS-PAGE). The nucleocapsid protein (C, 13,500 Da), membrane protein (M, 8,700 Da) and envelope protein (E, 53,000 Da) bands were seen in the SDS-PAGE (Figure 3, panel A). Envelope antigens (E) were detected by Western blotting with mouse anti-JE virus monoclonal antibody (Figure 3, panel C). Virus positive fractions, fraction Nos.4 to 9, in which other protein bands except viral proteins were not apparent in silver stained gel (Figure 3, panel B) were pooled, and assayed for protein concentration by Lowry method. Detailed results are shown from two purifications from infected Vero cultures either concentrated with tangential flow ultrafiltration or by PEG8000 precipitation (Tables 3 and 4). Purified virus was diluted with two volumes of PBS, added to the final 0.01% of Tween80, and filtered through a $0.22\text{ }\mu\text{m}$ filter.

25

Table 3. Purification of JE virus by concentration with tangential flow ultrafiltration.

Sample	Total Volume (ml)	Total pfu	%Yield (pfu)	Total protein (mg)	%Yield (protein)	Specific Activity (pfu/mg)
Pooled culture supernatant	10,000	4.4×10^{11}	100	600	100	7.3×10^7

	Filtron concentrate	200	4.0×10^{11}	90	280	47	1.4×10^8
	Sucrose gradient pool	500	3.8×10^{11}	86	42	7	9.0×10^9
5	0.22 μ filtration	50	2.4×10^{11}	55	23	3.8	1.0×10^{10}

Table 4. Purification of JE virus by concentration with PEG8000 precipitation.

Sample	Total Volume (ml)	Total pfu	%Yield (pfu)	Total protein (mg)	%Yield (protein)	Specific Activity (pfu/mg)
Pooled culture supernatant	10,000	4.4×10^{11}	100	600	100	7.3×10^7
PEC precipitate	200	2.7×10^{11}	61	40	6.7	6.8×10^9
Sucrose gradient pool	500	2.5×10^{11}	56	15	2.5	1.7×10^{10}
0.22 μ filtration	50	1.6×10^{11}	41	12	2	1.3×10^{10}

15

20

25

The virus preparations were compared for relative purity using specific activity measurements (i.e., pfu/mg protein). Virus purified from concentrate by ultrafiltration had about the same activity as virus purified from concentrate by PEG8000 precipitation. Also the purity of the pooled purified viruses was estimated by testing for Vero cell originated chromosomal DNA and protein. The results showed that contents of host cellular DNA and protein are as low as 2.5 pg and 2 ng per 5 μ g of purified JE virus respectively regardless of method of concentration, which demonstrated that both purification methods described above effectively removed other impurities from viral antigen. However in terms of protein yield of purified virus, the purification method using ultrafiltration is 2-fold better than the purification method involving PEG8000 precipitation.

EXAMPLE 4**Virus inactivation**

Purified virus was either directly used for preparation of live attenuated vaccine after dialysis with PBS or inactivated with formaldehyde for preparation of inactivated vaccine. Inactivation with 0.018% formaldehyde was carried out at 22°C or 4°C. Samples were taken at regular intervals and assayed directly for infectious virus by plaque titration (Figure 4). Samples which were negative by direct plaque assay were subjected to blind passage on Vero cell monolayers in order to amplify low levels of virus and then re-plaqued. It was found that 4 days at 22°C or 46 days at 4°C were required for complete inactivation of infectivity (Tables 5 and 6). The antigenicity of the virus was monitored during inactivation by testing samples with the antigen spot blot assay and polyclonal antisera. By this assay there appeared to be no detectable losses in antigenicity after exposure to 0.018% formaldehyde for up to 10 days at 22°C or 15 days at 4°C.

Inactivation with formaldehyde under these conditions was carried out for at least 7 days at 22°C or 60 days at 4°C, giving a margin of safety. After inactivation, free formaldehyde in the samples was neutralized by the addition of 0.038% of sodium metabisulfite. Dialysis was carried out concurrently with PBS and then filtered through a 0.22 µm filter.

Table 5. Formaldehyde inactivation of JE virus, CJ50003 at 4°C

Day	JE virus (-HCHO)	JE virus (+HCHO)	Amplification
0	3.2×10^8	3.2×10^8	+
0.5	2.6×10^8	3.2×10^6	+
1	1.52×10^8	7.9×10^5	+
25	2.4×10^8	4.8×10^5	+
2	2.8×10^8	6.4×10^4	+
3	2.6×10^8	4.3×10^3	+
4	1.9×10^8	1300	+
5	2.4×10^8	285	+
30	2.8×10^8	480	+

	7	1.5×10^8	200	+
	11	1.5×10^8	0	+
	22	1.4×10^8	0	+
	32	1.2×10^8	0	+
5	46	1.0×10^8	0	-
	60	1.0×10^8	0	-

Table 6. Formaldehyde inactivation of JE virus at 22°C

	Hour	JE virus (-HCHO)	JE virus (+HCHO)	Amplification
10	0	3.2×10^8	3.2×10^8	+
	3	3.0×10^8	1.3×10^6	+
	6	2.7×10^8	1.1×10^5	+
	12	2.5×10^8	3.5×10^5	+
	24	1.2×10^8	140	+
15	36	1.2×10^8	0	+
	48	1.2×10^8	0	+
	72	1.1×10^8	0	+
	96	1.1×10^8	0	-
	360	1.0×10^8	0	-

20

EXAMPLE 5**Immunogenicity of CJ50003 purified, inactivated virus (PIV) and live attenuated virus (LAV) in mice**

25 The immunogenicities of LAV and PIV were then tested in mice with previously commercialized Biken inactivated vaccine. Groups of 20 six-week-old BALB/c mice were immunized intraperitoneally (i.p.) with three kinds of immunogen. Immunization was done with two inoculations without an adjuvant at intervals of 2 weeks. Two weeks post second immunization sera were obtained from each group of mice, pooled and subsequently tested for the presence of neutralizing antibodies by PRNT method (Table

7). As shown in Table 7, there was no significant difference in neutralizing antibody titer between groups which received three kinds of immunogen.

Table 7. Induction of neutralizing antibodies in mice immunized with PIV or LAV

5	Immunogen	Dose	Titers of neutralizing antibodies ^a
PIV	5 µg		1:320
PIV	10 µg		1:320
LAV	5 µg		1:320
LAV	10 µg		1: 640
10	Biken vaccine ^b	1 dose	1: 320

a: Titer of neutralizing antibody is defined as the reciprocal of serum dilution resulting in 50% reduction of mouse brain passaged Nakayama virus plaques .

b: Biken vaccine 1 dose contains 5 µg of viral protein (TCA-precipitable) according to the manufacturer.

15

The Immunogenicity of PIV was further tested in mice. Adult, inbred mice were immunized with various dilutions of inactivated virus with or without an alum adjuvant. Groups of 20 six-week-old BALB/c mice were immunized subcutaneously with 500, 50, and 5 ng of PIV either in saline or saline with aluminum hydroxide (Rehydragel).

20 Mice received two inoculations spaced 3 weeks apart. Sera were pooled from each group of mice at 3 weeks post second immunization, and tested for the presence of neutralizing antibodies with mouse brain passaged Nakayana strain as neutralized virus (Table 8). PIV was better than Biken vaccine in all doses and adjuvant significantly improved the immune response of mice to 50 and 500 ng of PIV about 4 and 8 fold, respectively.

25

Table 8. Comparison of the titer of neutralizing antibody in mice immunized with PIV with or without alum hydroxide.

Immunogen	Dose	Titers of neutralizing antibodies ^a
-----------	------	--

	PIV	500 ng	1:160
	PIV	50 ng	1:40
	PIV	5 ng	1:20
	PIV + alum	500 ng	1: 1280
5	PIV + alum	50 ng	1: 160
	PIV + alum	5 ng	1: 20
	Biken vaccine	1/10 dose	1: 80
	Biken vaccine	1/100 dose	1: 10
	Biken vaccine	1/1000 dose	1: 10

10 a: Titer of neutralizing antibody is defined as the reciprocal of serum dilution resulting in 50% reduction of mouse brain passaged Nakayama virus plaques.

b: Biken vaccine 1 dose contains 5 μ g of viral protein (TCA-precipitable) according to the manufacturer.

15 The *in vivo* protective efficacy of PIV was then tested in BALB/c mice. For protection assays, groups of 10 three-week-old BALB/c mice were inoculated subcutaneously in the hindquarters with inactivated JE viruses in saline or saline with aluminum hydroxide (Rehydragel). Age-matched controls were inoculated with PBS or non-specific antigens in alum. Mice were boosted with an equivalent dose three weeks later. The mice were challenged at 3 weeks post immunization by intracranial inoculation with 500 pfu of the mouse neurovirulent JE virus (Nakayama, mouse brain adapted) contained in 30 μ l of PBS. Challenged mice were monitored daily for morbidity and mortality for up to twenty-one days. As shown in Table 9, mice immunized with 50 ng of PIV showed 90% of protection. Furthermore, mice immunized with 50 and 5 ng of PIV mixed with alum showed 100% and 70% protection, respectively while 1/100 dose of Biken vaccine protected just 50% of immunized mice. In comparison, all mice in the control group became sick and died beginning at five to seven days post-challenge.

Table 9. Protection of vaccinated mice against challenge
with Nakayama virus^a Immunogen

	Immunogen	Dose	Survivors
	Control ^b	N/A	0/10
5	PIV	500 ng	10/10
	PIV	50 ng	9/10
	PIV	5 ng	3/10
	PIV + alum	500 ng	10/10
	PIV + alum	50 ng	10/10
10	PIV + alum	5 ng	7/10
	Biken vaccine ^c	1/10 dose	10/10
	Biken vaccine	1/100 dose	5/10
	Biken vaccine	1/1000 dose	3/10

a: Mice immunized with 2 inoculations of test vaccines spaced 3 weeks apart, then challenged with 500 pfu of mouse-neurovirulent Nakayama virus.

b: Age-matched controls were inoculated with PBS or non-specific antigens in alum

c: Biken vaccine 1 dose contains 5 µg of viral protein (TCA-precipitable) according to the manufacturer .

20 To investigate immunologic stability of CJ50003 virus over Vero cell passages, viruses with various passage numbers in Vero cell were independently purified and the immunogenicities were evaluated by the method as described in Table 8. As shown in Table 10, there was no remarkable difference in the ability to elicit neutralizing antibodies among vaccines prepared from the viruses with different virus passage numbers in Vero cell, indicating that CJ50003 virus is very stable over Vero cell passages in terms of immunogenicity.

Table 10. Vaccine potencies prepared with JE viruses with different virus passage numbers in Vero cells

Immunogen ^a	Dose	Titers of neutralizing antibodies ^b		S.d. ^c
		5	10	
PIV - 4ps	0.5 µg	1:150	20	
PIV - 6ps	0.5 µg	1:145	15	
PIV - 15ps	0.5 µg	1:130	28	
PIV - 20ps	0.5 µg	1:140	18	
PIV - 30ps	0.5 µg	1:160	13	

10 a: Immunogen (PIV -Xps); purified inactivated vaccine prepared with CJ50003 virus of which passage number in Vero cells is X.

15 b: Titer of neutralizing antibody is defined as the reciprocal of serum dilution resulting in 50% reduction of mouse brain passaged Nakayama virus plaques and mean values of results from three separate experiments are taken. 50% endpoint is determined by Reed and Muench method.

c: Standard deviation

The results presented here suggest that both an inactivated JE virus vaccine and live attenuated vaccine using CJ50003 strain show promise. Relatively fast and efficient processes were developed for growing JE virus in Vero cell, concentrating and purifying them to a degree which may be suitable for human use and inactivating them without measurable loss in antigenicity. These preparations were found to be immunogenic and protective in mice.

WHAT IS CLAIMED IS:

1. An attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell.

5

2. The attenuated Japanese encephalitis virus according to claim 1 characterized in that multiplicity is more than $1 \times 10(7)$ PFU/ml in Vero cells and LD_{50}/pfu for young adult mouse is less than 0.000001.

10

3. The attenuated Japanese encephalitis virus according to claims 1 or 2 wherein is CJ50003.

4. A Japanese encephalitis vaccine comprising the attenuated Japanese encephalitis virus according to claim 1.

15

5. The vaccine according to claim 4 wherein the virus is inactivated by an inactivating agent.

20


6. The vaccine according to claim 4 wherein the virus is live-attenuated JE virus untreated by an inactivating agent.

7. The vaccine according to claims 4, 5 or 6 which further comprises pharmaceutically acceptable additives.

25


30

1/4

Fig 1.

2/4

Fig 2.



3/4

Fig 3.




A**B****C**

Fig 4.